{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:57:00Z","timestamp":1790452620167,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"38","license":[{"start":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T00:00:00Z","timestamp":1564444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T00:00:00Z","timestamp":1564444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["05A1-CAPP19-014"],"award-info":[{"award-number":["05A1-CAPP19-014"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["06A1-CAPP19-014"],"award-info":[{"award-number":["06A1-CAPP19-014"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["104-2321-B-400-019-MY3"],"award-info":[{"award-number":["104-2321-B-400-019-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1038\/s41388-019-0900-9","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T10:03:13Z","timestamp":1564480993000},"page":"6550-6565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors"],"prefix":"10.1038","volume":"38","author":[{"given":"Yuan-Shuo","family":"Hsueh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Hua","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Shen","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Sunny","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan Alfred","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Tzong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,30]]},"reference":[{"key":"900_CR1","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0140-6736(07)60780-6","volume":"369","author":"BP Rubin","year":"2007","unstructured":"Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007;369:1731\u201341.","journal-title":"Lancet"},{"key":"900_CR2","first-page":"1293","volume":"15","author":"T Nishida","year":"2000","unstructured":"Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol. 2000;15:1293\u2013301.","journal-title":"Histol Histopathol"},{"key":"900_CR3","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1200\/JCO.2007.13.4403","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620\u20135.","journal-title":"J Clin Oncol"},{"key":"900_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1634\/theoncologist.12-6-719","volume":"12","author":"S Sleijfer","year":"2007","unstructured":"Sleijfer S, Wiemer E, Seynaeve C, Verweij J. Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. Oncologist. 2007;12:719\u201326.","journal-title":"Oncologist"},{"key":"900_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295\u2013302.","journal-title":"Lancet"},{"key":"900_CR6","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1038\/sj.onc.1207525","volume":"23","author":"A Duensing","year":"2004","unstructured":"Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S, et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene. 2004;23:3999\u20134006.","journal-title":"Oncogene"},{"key":"900_CR7","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.1038\/sj.onc.1206587","volume":"22","author":"N Casteran","year":"2003","unstructured":"Casteran N, De Sepulveda P, Beslu N, Aoubala M, Letard S, Lecocq E, et al. Signal transduction by several KIT juxtamembrane domain mutations. Oncogene. 2003;22:4710\u201322.","journal-title":"Oncogene"},{"key":"900_CR8","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/ncb0901-802","volume":"3","author":"SY Lin","year":"2001","unstructured":"Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol. 2001;3:802\u20138.","journal-title":"Nat Cell Biol"},{"key":"900_CR9","doi-asserted-by":"publisher","first-page":"ra10","DOI":"10.1126\/scisignal.2000628","volume":"3","author":"B Sehat","year":"2010","unstructured":"Sehat B, Tofigh A, Lin Y, Trocme E, Liljedahl U, Lagergren J, et al. SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci Signal. 2010;3:ra10.","journal-title":"Sci Signal"},{"key":"900_CR10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/embor.2011.251","volume":"13","author":"D Warsito","year":"2012","unstructured":"Warsito D, Sjostrom S, Andersson S, Larsson O, Sehat B. Nuclear IGF1R is a transcriptional co-activator of LEF1\/TCF. EMBO Rep. 2012;13:244\u201350.","journal-title":"EMBO Rep"},{"key":"900_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3390\/cancers2020233","volume":"2","author":"R Sarfstein","year":"2010","unstructured":"Sarfstein R, Belfiore A, Werner H. Identification of insulin-like growth factor-I receptor (IGF-IR) gene promoter-binding proteins in estrogen receptor (ER)-positive and ER-depleted breast cancer cells. Cancers (Basel). 2010;2:233\u201361.","journal-title":"Cancers (Basel)"},{"key":"900_CR12","doi-asserted-by":"publisher","first-page":"11723","DOI":"10.18632\/oncotarget.2607","volume":"5","author":"YS Hsueh","year":"2014","unstructured":"Hsueh YS, Chang HH, Chiang NJ, Yen CC, Li CF, Chen LT. MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors. Oncotarget. 2014;5:11723\u201336.","journal-title":"Oncotarget"},{"key":"900_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.4161\/auto.22802","volume":"9","author":"YS Hsueh","year":"2013","unstructured":"Hsueh YS, Yen CC, Shih NY, Chiang NJ, Li CF, Chen LT. Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors. Autophagy. 2013;9:220\u201333.","journal-title":"Autophagy"},{"key":"900_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ccr.2010.03.008","volume":"17","author":"S Liu","year":"2010","unstructured":"Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, et al. Sp1\/NFkappaB\/HDAC\/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 2010;17:333\u201347.","journal-title":"Cancer Cell"},{"key":"900_CR15","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/0092-8674(95)90511-1","volume":"80","author":"JE Thompson","year":"1995","unstructured":"Thompson JE, Phillips RJ, Erdjument-Bromage H, Tempst P, Ghosh S. I kappa B-beta regulates the persistent response in a biphasic activation of NF-kappa B. Cell. 1995;80:573\u201382.","journal-title":"Cell"},{"key":"900_CR16","doi-asserted-by":"publisher","first-page":"pe1","DOI":"10.1126\/stke.11pe1","volume":"1","author":"G Natoli","year":"2008","unstructured":"Natoli G, Chiocca S. Nuclear ubiquitin ligases, NF-kappaB degradation, and the control of inflammation. Sci Signal. 2008;1:pe1.","journal-title":"Sci Signal"},{"key":"900_CR17","doi-asserted-by":"publisher","first-page":"6845","DOI":"10.1038\/sj.onc.1203224","volume":"18","author":"FE Chen","year":"1999","unstructured":"Chen FE, Ghosh G. Regulation of DNA binding by Rel\/NF-kappaB transcription factors: structural views. Oncogene. 1999;18:6845\u201352.","journal-title":"Oncogene"},{"key":"900_CR18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1146\/annurev-biophys-083012-130338","volume":"42","author":"J Napetschnig","year":"2013","unstructured":"Napetschnig J, Wu H. Molecular basis of NF-kappaB signaling. Annu Rev Biophys. 2013;42:443\u201368.","journal-title":"Annu Rev Biophys"},{"key":"900_CR19","first-page":"155","volume":"17","author":"PS Chen","year":"2017","unstructured":"Chen PS, Chang HH, Huang CC, Lee CC, Lee SY, Chen SL, et al. A longitudinal study of the association between the GNB3 C825T polymorphism and metabolic disturbance in bipolar II patients treated with valproate. Pharm J. 2017;17:155\u201361.","journal-title":"Pharm J"},{"key":"900_CR20","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1111\/j.1582-4934.2008.00603.x","volume":"13","author":"J Jones","year":"2009","unstructured":"Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D, et al. Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix. J Cell Mol Med. 2009;13:2342\u201352.","journal-title":"J Cell Mol Med"},{"key":"900_CR21","doi-asserted-by":"publisher","first-page":"6774","DOI":"10.1007\/s12035-015-9600-9","volume":"53","author":"CY Wang","year":"2016","unstructured":"Wang CY, Cheng CW, Wang WH, Chen PS, Tzeng SF. Postnatal stress induced by injection with valproate leads to developing emotional disorders along with molecular and cellular changes in the hippocampus and amygdala. Mol Neurobiol. 2016;53:6774\u201385.","journal-title":"Mol Neurobiol"},{"key":"900_CR22","first-page":"219","volume":"8","author":"YW Chen","year":"2014","unstructured":"Chen YW, Lin HC, Ng MC, Hsiao YH, Wang CC, Gean PW, et al. Activation of mGluR2\/3 underlies the effects of N-acetylcystein on amygdala-associated autism-like phenotypes in a valproate-induced rat model of autism. Front Behav Neurosci. 2014;8:219.","journal-title":"Front Behav Neurosci"},{"key":"900_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jmgm.2004.04.003","volume":"23","author":"R Foster","year":"2004","unstructured":"Foster R, Griffith R, Ferrao P, Ashman L. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. J Mol Graph Model. 2004;23:139\u201352.","journal-title":"J Mol Graph Model"},{"key":"900_CR24","first-page":"639","volume":"7","author":"CD Mol","year":"2004","unstructured":"Mol CD, Fabbro D, Hosfield DJ. Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors. Curr Opin Drug Disco Devel. 2004;7:639\u201348.","journal-title":"Curr Opin Drug Disco Devel"},{"key":"900_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065762","volume":"8","author":"YS Hsueh","year":"2013","unstructured":"Hsueh YS, Lin CL, Chiang NJ, Yen CC, Li CF, Shan YS, et al. Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations. PLoS ONE. 2013;8:e65762.","journal-title":"PLoS ONE"},{"key":"900_CR26","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1158\/1535-7163.MCT-11-0148","volume":"10","author":"G Floris","year":"2011","unstructured":"Floris G, Debiec-Rychter M, Wozniak A, Stefan C, Normant E, Faa G, et al. The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors. Mol cancer Ther. 2011;10:1897\u2013908.","journal-title":"Mol cancer Ther"},{"key":"900_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.canlet.2015.02.044","volume":"361","author":"Y Dong","year":"2015","unstructured":"Dong Y, Liang C, Zhang B, Ma J, He X, Chen S, et al. Bortezomib enhances the therapeutic efficacy of dasatinib by promoting c-KIT internalization-induced apoptosis in gastrointestinal stromal tumor cells. Cancer Lett. 2015;361:137\u201346.","journal-title":"Cancer Lett"},{"key":"900_CR28","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1158\/1535-7163.MCT-15-0321","volume":"14","author":"M Le Gall","year":"2015","unstructured":"Le Gall M, Crepin R, Neiveyans M, Auclair C, Fan Y, Zhou Y, et al. Neutralization of KIT oncogenic signaling in leukemia with antibodies targeting KIT membrane proximal domain 5. Mol cancer Ther. 2015;14:2595\u2013605.","journal-title":"Mol cancer Ther"},{"key":"900_CR29","doi-asserted-by":"publisher","first-page":"11093","DOI":"10.1158\/0008-5472.CAN-07-1576","volume":"67","author":"F Chen","year":"2007","unstructured":"Chen F, Castranova V. Nuclear factor-kappaB, an unappreciated tumor suppressor. Cancer Res. 2007;67:11093\u20138.","journal-title":"Cancer Res"},{"key":"900_CR30","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1073\/pnas.95.5.2307","volume":"95","author":"CS Seitz","year":"1998","unstructured":"Seitz CS, Lin Q, Deng H, Khavari PA. Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc Natl Acad Sci USA. 1998;95:2307\u201312.","journal-title":"Proc Natl Acad Sci USA"},{"key":"900_CR31","doi-asserted-by":"publisher","first-page":"37142","DOI":"10.1074\/jbc.M603631200","volume":"281","author":"F Chen","year":"2006","unstructured":"Chen F, Lu Y, Castranova V, Li Z, Karin M. Loss of Ikkbeta promotes migration and proliferation of mouse embryo fibroblast cells. J Biol Chem. 2006;281:37142\u20139.","journal-title":"J Biol Chem"},{"key":"900_CR32","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cell.2005.04.014","volume":"121","author":"S Maeda","year":"2005","unstructured":"Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell. 2005;121:977\u201390.","journal-title":"Cell"},{"key":"900_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ccr.2006.12.016","volume":"11","author":"T Luedde","year":"2007","unstructured":"Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, et al. Deletion of NEMO\/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2007;11:119\u201332.","journal-title":"Cancer Cell"},{"key":"900_CR34","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s13277-015-3921-1","volume":"37","author":"Y Du","year":"2016","unstructured":"Du Y, Zhu M, Zhou X, Huang Z, Zhu J, Xu J, et al. miR-20a enhances cisplatin resistance of human gastric cancer cell line by targeting NFKBIB. Tumour Biol. 2016;37:1261\u20139.","journal-title":"Tumour Biol"},{"key":"900_CR35","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.18632\/oncotarget.1938","volume":"5","author":"HS Isaksson","year":"2014","unstructured":"Isaksson HS, Sorbe B, Nilsson TK. Whole genome expression profiling of blood cells in ovarian cancer patients -prognostic impact of the CYP1B1, MTSS1, NCALD, and NOP14. Oncotarget. 2014;5:4040\u20139.","journal-title":"Oncotarget"},{"key":"900_CR36","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1038\/onc.2010.55","volume":"29","author":"CC Lee","year":"2010","unstructured":"Lee CC, Jan HJ, Lai JH, Ma HI, Hueng DY, Lee YC, et al. Nodal promotes growth and invasion in human gliomas. Oncogene. 2010;29:3110\u201323.","journal-title":"Oncogene"},{"key":"900_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-41","volume":"8","author":"F Lerebours","year":"2008","unstructured":"Lerebours F, Vacher S, Andrieu C, Espie M, Marty M, Lidereau R, et al. NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer. 2008;8:41.","journal-title":"BMC Cancer"},{"key":"900_CR38","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3390\/cells3010112","volume":"3","author":"S Liberati","year":"2014","unstructured":"Liberati S, Morelli MB, Amantini C, Farfariello V, Santoni M, Conti A, et al. Loss of TRPV2 homeostatic control of cell proliferation drives tumor progression. Cells. 2014;3:112\u201328.","journal-title":"Cells"},{"key":"900_CR39","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.1073\/pnas.1203203109","volume":"109","author":"J Kim","year":"2012","unstructured":"Kim J, Villadsen R, Sorlie T, Fogh L, Gronlund SZ, Fridriksdottir AJ, et al. Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity. Proc Natl Acad Sci USA. 2012;109:6124\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 1","key":"900_CR40","doi-asserted-by":"publisher","first-page":"E1392","DOI":"10.1002\/hed.24232","volume":"38","author":"MA Pavon","year":"2016","unstructured":"Pavon MA, Parreno M, Tellez-Gabriel M, Leon X, Arroyo-Solera I, Lopez M, et al. CKMT1 and NCOA1 expression as a predictor of clinical outcome in patients with advanced-stage head and neck squamous cell carcinoma. Head Neck. 2016;38(Suppl 1):E1392\u20131403.","journal-title":"Head Neck"},{"key":"900_CR41","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/pbc.24282","volume":"60","author":"K Sugito","year":"2013","unstructured":"Sugito K, Kawashima H, Uekusa S, Yoshizawa S, Hoshi R, Furuya T, et al. Identification of aberrant methylation regions in neuroblastoma by screening of tissue-specific differentially methylated regions. Pedia Blood Cancer. 2013;60:383\u20139.","journal-title":"Pedia Blood Cancer"},{"key":"900_CR42","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.gastro.2015.04.006","volume":"149","author":"Y Hayashi","year":"2015","unstructured":"Hayashi Y, Bardsley MR, Toyomasu Y, Milosavljevic S, Gajdos GB, Choi KM, et al. Platelet-derived growth factor receptor-alpha regulates proliferation of gastrointestinal stromal tumor cells with mutations in KIT by stabilizing ETV1. Gastroenterology. 2015;149:420\u201332 e416.","journal-title":"Gastroenterology"},{"key":"900_CR43","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/labinvest.3780461","volume":"82","author":"T Taguchi","year":"2002","unstructured":"Taguchi T, Sonobe H, Toyonaga S, Yamasaki I, Shuin T, Takano A, et al. Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor. Lab Investig. 2002;82:663\u20135.","journal-title":"Lab Investig"},{"key":"900_CR44","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1158\/0008-5472.CAN-13-0371","volume":"73","author":"S Rusakiewicz","year":"2013","unstructured":"Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 2013;73:3499\u2013510.","journal-title":"Cancer Res"},{"key":"900_CR45","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s13277-013-1235-8","volume":"35","author":"LJ Ma","year":"2014","unstructured":"Ma LJ, Lee SW, Lin LC, Chen TJ, Chang IW, Hsu HP, et al. Fibronectin overexpression is associated with latent membrane protein 1 expression and has independent prognostic value for nasopharyngeal carcinoma. Tumour Biol. 2014;35:1703\u201312.","journal-title":"Tumour Biol"},{"key":"900_CR46","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/ncb3445","volume":"19","author":"AH Rezaeian","year":"2017","unstructured":"Rezaeian AH, Li CF, Wu CY, Zhang X, Delacerda J, You MJ, et al. A hypoxia-responsive TRAF6-ATM-H2AX signalling axis promotes HIF1alpha activation, tumorigenesis and metastasis. Nat Cell Biol. 2017;19:38\u201351.","journal-title":"Nat Cell Biol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-019-0900-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-019-0900-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-019-0900-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:16:50Z","timestamp":1684617410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-019-0900-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,30]]},"references-count":46,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["900"],"URL":"https:\/\/doi.org\/10.1038\/s41388-019-0900-9","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,30]]},"assertion":[{"value":"3 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Li-Tzong Chen reports personal fees from Ono Pharmaceutical, personal fees from Bristol-Myers Squibb, personal fees from Eli Lilly, personal fees from MSD, PharmaEngine, personal fees from Merrimack, grants and personal fees from TTY Biopharm, grants and personal fees from Syncore, personal fees from Five Prime, grants and personal fees from Novartis, personal fees from Pfizer, grants from GlaxoSmithKline, grants from Merck Serono, grants from Polaris, outside the submitted work. The remaining authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}